MMB-FUBINACA (FUB-AMB; Item No. 9001960) is an analytical reference standard that is structurally classified as a synthetic cannabinoid. It is the methyl ester analog of AB-FUBINACA (Item No. 14039), where the terminal amide group of the valine has been replaced with a methyl ester. The physiological and toxicological properties of this compound are not known. This product is intended for forensic and research applications.



FUB-AMB (CAS: 1971007-92-7) is a synthetic cannabinoid that was
first documented (as a derivative) in international patent WO 2009/106980-A2 issued to Ingrid
Buchler and colleagues at Pfizer on September 3, 2009.1
FUB-AMB is also referred to as MMBFUBINACA and AMB-FUBINACA.

The most likely route of administration for FUB-AMB is inhalation via
smoking the chemical after it has been sprayed on plant material or vaping it after formulation in
liquid. Dosage required for pharmacological effects in humans is unknown. Because the most
common route of administration for FUB-AMB involves heating an e-liquid containing the chemical
or burning plant material that contains the chemical, thermolytic conversion is of concern. A
recent study suggests that heating FUB-AMB to temperatures that could occur with smoking (400
C) released its methyl-ester substituent to produce several thermal degradants as well as cyanide.
The degree to which cyanide would reach toxicological concentrations in users is unknown.
Almost nothing in known about the specific pharmacokinetics of FUB-AMB. Based upon analysis of
blood and urine of patients who received medical attention during a cluster of FUB-AMB
overdoses in New York City in July 2016, metabolism is rapid and extensive. Hydrolysis results in
formation of a de-esterified acid metabolite, 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-
methylbutanoic acid, which was detected in all patients.

FUB-AMB is a potent CB1 receptor agonist, with reported binding affinity (Ki) of 10.04 nM and
0.786 nM in hCB1 and hCB2 receptors, respectively. It is a full agonist in functional tests of CB1
and CB2 receptor activation, as demonstrated by FUB-AMB-induced [35S]GTPS binding (both
receptors), inhibition of forskolin-stimulated cyclic adenosine monophosphate (cAMP) (CB1
receptor), and opening of G protein-gated inwardly rectifying potassium channels (GIRKs) (both
receptors expressed in mouse AtT20-FlpIn neuroblastoma cells). FUB-AMB was potent at
activating the CB1 receptor G-protein (EC50 = 0.54 nM), inhibiting cAMP (EC50 = 0.63 nM), and Stimulated.

FUB-AMB is an indazole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor. Another synonym used for FUB-AMB in the expert circles is AMB-FUBINACA , and simple chemical formula of the substance is summed up as C21H22FN3O3 . Its official designation in the IUPAC system is defined as methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate, with the molecular weight determined to be 383.41 g/mol. The product is delivered as a solution in acetonitrile, at a professional-grade purity (higher than 98%) ,or as a powder with a purity above 99.5%. UB-AMB was identified by Louisiana crime labs in an herbal mixture labelled “Train Wreck2” in 2014 and was banned as a controlled dangerous substance as of July 3rd, 2014. The physiological and toxicological properties of this compound are mostly unknown, have no known medicinal value and as such there is no accepted dose. This product is intended for forensic and research applications…

Additional information


10 g, 100 g, 1000 g, 25 g, 250 g, 50 g, 500 g